Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SLC13A5 | Q86YT5 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL4900000 | 0.89 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL2767900 | 0.85 | ALDH1A1 (0.94) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL31538120 | 0.84 | ALDH1A1 (0.65) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL28566996 | 0.83 | ALDH1A1 (0.79) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL6429505 | 0.83 | ALDH1A1 (0.88) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL7155667 | 0.83 | ALDH1A1 (0.88) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL1243198 | 0.83 | ALDH1A1 (0.88) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL15660063 | 0.83 | ALDH1A1 (0.88) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL6838001 | 0.83 | ALDH1A1 (0.88) | ALDH1A1LMNAMEN1KMT2AHMGCR | |
| Citric Acid SCHEMBL591542 | 0.83 | ALDH1A1 (0.88) | ALDH1A1LMNAMEN1KMT2AHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116120466-A | Purification method of GLP1-GCGR fusion protein | 江苏恒瑞医药股份有限公司 | 2023-05-16 | — | — | CN | claimed |
| WO-2013059534-A1 | GLUCOSE BIOSENSOR WITH IMPROVED SHELF LIFE | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | WO | claimed |
| US-20130098775-A1 | Glucose biosensor with improved shelf life | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | US | claimed |
| EP-0913436-B1 | Improved ink compositions for thermal ink jet printing | XEROX CORP (US) | 2003-11-12 | — | — | EP | claimed |
| EP-0913437-B1 | Improved ink compositions for thermal ink jet printing | XEROX CORP (US) | 2002-12-11 | — | — | EP | claimed |
| US-5935861-A | MIXTURE OF SOLUBILIZER AND 2-METHYL-3-NITROANILINE DIAZONIUM ION; FOR SPECTROPHOTOMETRIC DETECTION AND QUANTIFICATION OF BILIRUBIN AND DIAGNOSIS OF LIVER, GALL BLADDER AND INTESTINAL DISORDERS | BOEHRINGER MANNHEIM CORPORATION (US) | 1999-08-10 | — | — | US | claimed |
| US-4892833-A | BILIRUBIN, COUPLING WITH DIAZONIUM SALT, BUFFER | BOEHRINGER MANNHEIM GMBH (DE) | 1990-01-09 | — | — | US | claimed |
| US-20240237634-A1 | PROTEIN-FREE SEMEN CRYOPRESERVATION | UNIVERSITY OF SASKATCHEWAN (CA) | 2024-07-18 | — | — | US | disclosed |
| US-11819019-B2 | Protein-free semen cryopreservation | UNIVERSITY OF SASKATCHEWAN (CA) | 2023-11-21 | — | — | US | disclosed |
| CN-116120466-A | Purification method of GLP1-GCGR fusion protein | 江苏恒瑞医药股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20210059241-A1 | PROTEIN-FREE SEMEN CRYOPRESERVATION | UNIVERSITY OF SASKATCHEWAN (CA) | 2021-03-04 | — | — | US | disclosed |
| CN-110177461-A | Sperm cell processing methods, devices, and related media compositions | 英格朗公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-106148997-A | A kind of high performance capillary electrophoresis splits the method for flurbiprofen enantiomers | 田东县浙缘农业科技有限公司 | 2016-11-23 | — | — | CN | disclosed |
| WO-1992011854-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-23 | — | — | WO | disclosed |
| US-5100469-A | Colorant, carrier and meso-erythritol or a trihydroxy compound | XEROX CORPORATION (US) | 1992-03-31 | — | — | US | disclosed |
| WO-1991017469-A1 | KIT FOR CONTACT LENSES | VEPEX CONTRACTOR LTD. (HU) | 1991-11-14 | — | — | WO | disclosed |
| US-5004685-A | Support with chromogen, peroxidatively active material, oxidase, ferrocyanide; measures amount of hydrogen peroxide produced by analyte | FUJI PHOTO FILM CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4892833-A | BILIRUBIN, COUPLING WITH DIAZONIUM SALT, BUFFER | BOEHRINGER MANNHEIM GMBH (DE) | 1990-01-09 | — | — | US | disclosed |
| WO-1989007762-A1 | PROCEDURE FOR PREDICTING THE RECURRENCE OF HUMAN CERVICA CARCINOMA | WAKE FOREST UNIVERSITY (US) | 1989-08-24 | — | — | WO | disclosed |
| US-4168205-A | REDOX REACTION IN PRESENCE OF ASCORBATE OXIDASE | BOEHRINGER MANNHEIM GMBH (DE) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210059241-A1 | PROTEIN-FREE SEMEN CRYOPRESERVATION | CETP, NASP, CHLSN | MEN1 2754/4885ALDH1A1 3797/4885LMNA 470/4885 |
| US-11819019-B2 | Protein-free semen cryopreservation | CETP, NASP, CHLSN | MEN1 2754/4885ALDH1A1 3797/4885LMNA 470/4885 |
| US-20240237634-A1 | PROTEIN-FREE SEMEN CRYOPRESERVATION | CETP, NASP, CHLSN | MEN1 2754/4885ALDH1A1 3797/4885LMNA 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.